Revlimid (lenalidomide) patent expiration date?

Revlimid® (lenalidomide) is marketed by Celgene/Bristol Myers Squibb for multiple myeloma (and related indications). Its original U.S. patent (for the core composition/use) is generally considered to have expired around 2012, and later “secondary” (formulation/process/method-of-use) patents kept additional exclusivity in place—which is why generic versions did not immediately appear in the U.S. after the first patent expiry.

That said, there isn’t one single universal “Revlimid patent expiration date” because there are multiple patents and exclusivities (e.g., method-of-use, formulation, pediatric/other exclusivities) with different end dates, and they also vary by country.

To give you the exact date you need, can you tell me:

1. Country (U.S., EU/UK, Canada, etc.)
2. Whether you mean brand Revlimid specifically or all forms (tablets/capsules, different strengths)
3. Which claim type you care about (e.g., composition, method of use, process, or generic entry/ANDA “patent cliff”)

If you want, I can also help interpret FDA Orange Book or patent listings to identify the controlling expiration(s) for the specific jurisdiction/strength.